Padraig R Warde

List of Publications by Year
in descending order

256 papers	18,760 citations	15504 65 h-index	12946 131 g-index
266 all docs	266 docs citations	266 times ranked	11858 citing authors

#	Article	IF	Citations
1	Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet, The, 2002, 360, 103-108.	13.7	1,617
2	Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin. New England Journal of Medicine, 1997, 337, 295-300.	27.0	1,455
3	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncology, The, 2010, 11, 1066-1073.	10.7	830
4	Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.. Journal of Clinical Oncology, 1992, 10, 890-895.	1.6	764
5	Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis. Journal of Clinical Oncology, 2002, 20, 4448-4452.	1.6	536
6	Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet, The, 2011, 378, 2104-2111.	13.7	522
7	Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 1884-1890.	1.6	521
8	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. European Urology, 2008, 53, 478-496.	1.9	488
9	Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. New England Journal of Medicine, 2012, 367, 895-903.	27.0	428
10	Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 6132-6138.	1.6	331
11	Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes. Journal of Clinical Oncology, 2009, 27, 3452-3458.	1.6	300
12	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. Journal of Clinical Oncology, 2015, 33, 51-57.	1.6	268
13	Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. International Journal of Radiation Oncology Biology Physics, 2007, 67, 942-953.	0.8	264
14	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. European Urology, 2008, 53, 497-513.	1.9	243
15	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. Journal of Clinical Oncology, 2017, 35, 2299-2305.	1.6	241
16	Dynamic Contrast-Enhanced Magnetic Resonance Imaging forÂLocalization of Recurrent Prostate Cancer After ExternalÂBeam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 425-430.	0.8	234
17	Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer. Clinical Cancer Research, 2012, 18, 2108-2114.	7.0	233
18	Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.. Journal of Clinical Oncology, 1990, 8, 1301-1309.	1.6	215

#	Article	IF	Citations
19	Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 2143-2150.	1.6	213
20	Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiotherapy and Oncology, 2001, 61, 127-133.	0.6	189
21	Predictive Model for Survival in Patients With Advanced Cancer. Journal of Clinical Oncology, 2008, 26, 5863-5869.	1.6	176
22	Stage I testicular seminoma: results of adjuvant irradiation and surveillance.. Journal of Clinical Oncology, 1995, 13, 2255-2262.	1.6	173
23	T1/T2 Glottic Cancer Managed by External Beam Radiotherapy: The Influence of Pretreatment Hemoglobin on Local Control. International Journal of Radiation Oncology Biology Physics, 1998, 41, 347-353.	0.8	169
24	A magnetic resonance imaging study of prostate deformation relative to implanted gold fiducial markers. International Journal of Radiation Oncology Biology Physics, 2007, 67, 48-56.	0.8	160
25	Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 5038-5045.	1.6	157
26	Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiotherapy and Oncology, 2001, 59, 51-60.	0.6	154
27	Portal imaging for evaluation of daily on-line setup errors and off-line organ motion during conformal irradiation of carcinoma of the prostate. International Journal of Radiation Oncology Biology Physics, 2001, 49, 869-884.	0.8	153
28	Anatomic Boundaries of the Clinical Target Volume (Prostate Bed) After Radical Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1090-1099.	0.8	146
29	A comprehensive systematic review of testicular germ cell tumor surveillance. Critical Reviews in Oncology/Hematology, 2007, 64, 182-197.	4.4	142
30	Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1084-1089.	0.8	139
31	Eliciting preferences for alternative drug therapies in oncology: Influence of treatment outcome description, elicitation technique and treatment experience on preferences. Journal of Chronic Diseases, 1987, 40, 811-818.	1.2	137
32	Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 58, 750-757.	0.8	129
33	Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Medicine, 2015, 4, 155-160.	2.8	129
34	Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer. Journal of Clinical Oncology, 2013, 31, 3490-3493.	1.6	124
35	A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology Biology Physics, 2004, 58, 674-681.	0.8	119
36	Canadian consensus guidelines for the management of testicular germ cell cancer. Canadian Urological Association Journal, 2013, 4, 19.	0.6	119

#	Article	IF	Citations
37	Magnetic resonance imaging (MRI) for localization of the prostatic apex: comparison to computed tomography (CT) and urethrography. Radiotherapy and Oncology, 1998, 47, 277-284.	0.6	117
38	Stage II Testicular Seminoma: Patterns of Recurrence and Outcome of Treatment. European Urology, 2004, 45, 754-760.	1.9	115
39	Pre-treatment risk stratification of prostate cancer patients: A critical review. Canadian Urological Association Journal, 2012, 6, 121-127.	0.6	115
40	Impact of Noninvasive Imaging on Increased Incidental Detection of Renal Cell Carcinoma. European Urology, 2000, 37, 521-527.	1.9	111
41	Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response. Cancer Research, 2007, 67, 6022-6025.	0.9	109
42	Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. Journal of Urology, 2018, 200, 126-135.	0.4	107
43	Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 5030-5037.	1.6	103
44	Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 303-309.	1.6	98
45	Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men. Journal of Urology, 2010, 184, 918-924.	0.4	97
46	A management approach to incompletely excised basal cell carcinomas of skin. International Journal of Radiation Oncology Biology Physics, 1991, 20, 423-428.	0.8	95
47	Radiation treatment of cervical lymph node metastases from an unknown primary: an analysis of outcome by treatment volume and other prognostic factors. Radiotherapy and Oncology, 1995, 35, 206-211.	0.6	95
48	Nonâ€“Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospitalâ€™s Experience. European Urology, 2011, 59, 556-562.	1.9	95
49	A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2002, 54, 9-13.	0.8	93
50	Ethmoid Sinus Cancer: Twenty-nine Cases Managed With Primary Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 1998, 41, 361-369.	0.8	91
51	Healthcare costs associated with prostate cancer: estimates from a populationâ€based study. BJU International, 2010, 105, 338-346.	2.5	91
52	Management of stage II seminoma.. Journal of Clinical Oncology, 1998, 16, 290-294.	1.6	88
53	Pain flare in patients with bone metastases after palliative radiotherapyâ€”a nested randomized control trial. Supportive Care in Cancer, 2007, 15, 451-455.	2.2	87
54	Management and Outcome Differences in Supraglottic Cancer Between Ontario, Canada, and the Surveillance, Epidemiology, and End Results Areas of the United States. Journal of Clinical Oncology, 2003, 21, 496-505.	1.6	84

#	Article	IF	Citations
55	Carcinoma of the maxillary antrum: a retrospective analysis of 110 cases. Radiotherapy and Oncology, 2000, 57, 167-173.	0.6	82
56	Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer and Prostatic Diseases, 2003, 6, 73-85.	3.9	80
57	Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer. Nature Medicine, 2021, 27, 999-1005.	30.7	78
58	PROGRESSION DETECTION OF STAGE I NONSEMINOMATOUS TESTIS CANCER ON SURVEILLANCE: IMPLICATIONS FOR THE FOLLOWUP PROTOCOL. Journal of Urology, 1999, 161, 472-476.	0.4	77
59	A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer, 2005, 104, 1894-1900.	4.1	77
60	Changes in apparent diffusion coefficient and T₂ relaxation during radiotherapy for prostate cancer. Journal of Magnetic Resonance Imaging, 2013, 37, 909-916.	3.4	74
61	Evidence-based guidelines for following stage 1 seminoma. Cancer, 2007, 109, 2248-2256.	4.1	73
62	Carcinoma of the prostate: Results of radical radiotherapy (1970â€“1985). International Journal of Radiation Oncology Biology Physics, 1993, 26, 203-210.	0.8	72
63	Results of a policy of surveillance in stage I testicular seminoma. International Journal of Radiation Oncology Biology Physics, 1993, 27, 11-15.	0.8	72
64	Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: Population-based outcomes study supporting need for intensified treatment schedules. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1002-1012.	0.8	69
65	The ten-year rule revisited: accuracy of cliniciansâ€™ estimates of life expectancy in patients with localized prostate cancer. Urology, 2002, 60, 258-263.	1.0	67
66	Spermatocytic Seminoma: A Review. European Urology, 2004, 45, 495-498.	1.9	66
67	Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey. Supportive Care in Cancer, 2012, 20, 2737-2746.	2.2	65
68	Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer, 2002, 94, 1997-2006.	4.1	64
69	Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiotherapy and Oncology, 2007, 85, 7-16.	0.6	64
70	Urethral carcinoma in women: results of treatment with primary radiotherapy. Radiotherapy and Oncology, 2000, 56, 29-35.	0.6	62
71	Image guided dose escalated prostate radiotherapy: still room to improve. Radiation Oncology, 2009, 4, 50.	2.7	57
72	Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1403-1407.	0.8	55

#	Article	IF	Citations
73	A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer, 2001, 92, 1484-1494.	4.1	54
74	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. European Urology, 2017, 71, 120-127.	1.9	54
75	Glottic cancer in Ontario, Canada and the SEER areas of the United States. Journal of Clinical Epidemiology, 2001, 54, 301-315.	5.0	53
76	Patient-Assessed Late Toxicity Rates and Principal Component Analysis After Image-Guided Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 690-698.	0.8	53
77	A Cinematic Magnetic Resonance Imaging Study of Milk of Magnesia Laxative and an Antiflatulent Diet to Reduce Intrafraction Prostate Motion. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1072-1078.	0.8	52
78	Pathological Predictors for Site of Local Recurrence After Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e441-e448.	0.8	52
79	Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clinical Cancer Research, 2003, 9, 2177-84.	7.0	52
80	Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy. Cancer, 2005, 104, 891-905.	4.1	51
81	Effects of longâ€term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. Cancer, 2017, 123, 237-244.	4.1	51
82	Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy. Journal of Clinical Oncology, 2015, 33, 582-587.	1.6	50
83	Validation of a Predictive Model for Survival in Metastatic Cancer Patients Attending an Outpatient Palliative Radiotherapy Clinic. International Journal of Radiation Oncology Biology Physics, 2009, 73, 280-287.	0.8	49
84	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	1.9	49
85	Salvage radiotherapy for PSA failure after radical prostatectomy. Radiotherapy and Oncology, 2001, 61, 107-116.	0.6	48
86	Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. BJU International, 2006, 97, 963-968.	2.5	48
87	A phase II study of localized prostate cancer treated to 75.6Gy with 3D conformal radiotherapy. Radiotherapy and Oncology, 2005, 76, 11-17.	0.6	47
88	Longâ€term impact of androgenâ€deprivation therapy on physical function and quality of life. Cancer, 2015, 121, 2350-2357.	4.1	47
89	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. Journal of Clinical Oncology, 2019, 37, 1919-1926.	1.6	47
90	Resource implications of palliative chemotherapy for ovarian cancer.. Journal of Clinical Oncology, 1997, 15, 1000-1007.	1.6	46

#	Article	IF	Citations
91	Role of epstein-barr virus in fine-needle aspirates of metastatic neck nodes in the diagnosis of nasopharyngeal carcinoma. Head and Neck, 1995, 17, 487-493.	2.0	45
92	Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma. Radiotherapy and Oncology, 2003, 68, 153-161.	0.6	45
93	Accuracy and sensitivity of finite element modelâ€based deformable registration of the prostate. Medical Physics, 2008, 35, 4019-4025.	3.0	45
94	Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study. Radiotherapy and Oncology, 2002, 63, 269-274.	0.6	44
95	Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. European Journal of Cancer, 2004, 40, 1674-1681.	2.8	43
96	Benign parotid adenomas: A review of the princess margaret hospital experience. Head and Neck, 1995, 17, 177-183.	2.0	42
97	Carcinoma-in-situ of the glottic larynx: results of treatment with radiation therapy. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1235-1238.	0.8	42
98	Management of decreased bone mineral density in men starting androgenâ€deprivation therapy for prostate cancer. BJU International, 2009, 103, 753-757.	2.5	42
99	SURVEILLANCE FOR STAGE I TESTICULAR SEMINOMA. Urologic Clinics of North America, 1998, 25, 425-433.	1.8	41
100	SCREENING WITH PROSTATE SPECIFIC ANTIGEN AND METASTATIC PROSTATE CANCER RISK: A POPULATION BASED CASE-CONTROL STUDY. Journal of Urology, 2005, 174, 495-499.	0.4	41
101	Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance. European Radiology, 2010, 20, 1624-1630.	4.5	41
102	Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nature Reviews Urology, 2015, 12, 193-204.	3.8	41
103	Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: Quality of life in a prospective phase I/II trial. Radiotherapy and Oncology, 2008, 87, 181-187.	0.6	40
104	Treatment burden in stage <scp>I</scp> seminoma: a comparison of surveillance and adjuvant radiation therapy. BJU International, 2013, 112, 1088-1095.	2.5	40
105	Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial. Journal of Clinical Oncology, 2015, 33, 2151-2157.	1.6	39
106	Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study. Supportive Care in Cancer, 2017, 25, 879-886.	2.2	39
107	Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. European Urology Oncology, 2021, 4, 483-491.	5.4	39
108	Results of radiotherapy for primary subglottic squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics, 2002, 52, 1245-1250.	0.8	38

#	Article	IF	Citations
109	Stage I Seminoma: Adjuvant Treatment is Effective but is it Necessary?. Journal of the National Cancer Institute, 2011, 103, 194-196.	6.3	38
110	Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporosis International, 2013, 24, 2571-2579.	3.1	38
111	Delivery of Cancer Care in Ontario, Canada, During the First Year of the COVID-19 Pandemic. JAMA Network Open, 2022, 5, e228855.	5.9	38
112	Outcome following radiotherapy in verrucous carcinoma of the larynx. International Journal of Radiation Oncology Biology Physics, 1995, 32, 611-617.	0.8	36
113	A survey of radiation treatment planning peer-review activities in a provincial radiation oncology programme: current practice and future directions. BMJ Open, 2013, 3, e003241.	1.9	36
114	Improvement in total positioning error for lateral prostatic fields using a soft immobilization device. Radiotherapy and Oncology, 1997, 44, 265-270.	0.6	34
115	The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis. Radiotherapy and Oncology, 2013, 109, 204-210.	0.6	34
116	Prevention and management of osteoporosis in men receiving androgen deprivation therapy: A survey of urologists and radiation oncologists. Urology, 2006, 68, 126-131.	1.0	33
117	No Role for Routine Chest Radiography in Stage I Seminoma Surveillance. European Urology, 2010, 57, 474-479.	1.9	33
118	Utility of serum tumor markers during surveillance for stage I seminoma. Cancer, 2012, 118, 5245-5250.	4.1	33
119	The Clinical Specialist Radiation Therapist (CSRT): A case study exploring the effectiveness of a new advanced practice role in Canada. Journal of Medical Radiation Sciences, 2018, 65, 86-96.	1.5	32
120	Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU International, 1999, 83, 438-448.	2.5	30
121	Does age influence the behaviour of localized prostate cancer?. BJU International, 2001, 87, 629-637.	2.5	30
122	A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies. Radiotherapy and Oncology, 2008, 88, 53-60.	0.6	30
123	Clinical Application of High-Dose, Image-Guided Intensity-Modulated Radiotherapy in High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 477-483.	0.8	29
124	A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. Radiotherapy and Oncology, 2008, 87, 173-180.	0.6	28
125	Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nature Reviews Clinical Oncology, 2011, 8, 107-113.	27.6	28
126	Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2016, 15, 147-155.	0.5	28

#	Article	IF	Citations
127	Recurrent prostate cancer following external beam radiotherapy. Urologic Clinics of North America, 2003, 30, 751-763.	1.8	27
128	The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer â€“ a systematic review. Radiotherapy and Oncology, 2002, 64, 239-250.	0.6	26
129	Appropriate radiation volume for stage IIA/B testicular seminoma. International Journal of Radiation Oncology Biology Physics, 2003, 56, 746-748.	0.8	26
130	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. European Urology Focus, 2018, 4, 995-1001.	3.1	26
131	Role of Principal Component Analysis in Predicting Toxicity in Prostate Cancer Patients Treated With Hypofractionated Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e415-e421.	0.8	25
132	A comparison of published head and neck stage groupings in laryngeal cancer using data from two countries. Journal of Clinical Epidemiology, 2002, 55, 533-544.	5.0	24
133	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. Practical Radiation Oncology, 2015, 5, e473-e482.	2.1	24
134	Adjuvant carboplatin in stage I seminoma. Lancet, The, 2005, 366, 267-268.	13.7	23
135	Management of Localized Seminoma, Stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology, 2011, 78, S435-S443.	1.0	23
136	Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors. Journal of Urology, 2015, 194, 386-391.	0.4	23
137	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiotherapy and Oncology, 2017, 122, 93-98.	0.6	23
138	The management of locally advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 1998, 4, 3-12.	1.6	22
139	Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy. Obstetrical and Gynecological Survey, 2013, 68, 34-35.	0.4	22
140	A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. BMC Cancer, 2015, 15, 312.	2.6	22
141	Management of testicular seminoma. Journal of Surgical Oncology, 1999, 17, 240-249.	1.4	21
142	Surveillance in stage I testicular seminoma. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 75-79.	1.6	21
143	Sex or survival. Cancer, 2010, 116, 1909-1917.	4.1	21
144	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	2.1	21

#	Article	IF	Citations
145	Information needs of men on androgen deprivation therapy. BJU International, 2012, 109, 1503-1509.	2.5	20
146	Predictors of breast radiotherapy plan modifications: Quality assurance rounds in a large cancer centre. Radiotherapy and Oncology, 2015, 114, 17-21.	0.6	20
147	ReCAP: Improving the Quality of Radiation Treatment for Patients in Ontario: Increasing Peer Review Activities on a Jurisdictional Level Using a Change Management Approach. Journal of Oncology Practice, 2016, 12, 81-82.	2.5	20
148	The Use of a Markov Process to Simulate and Assess Follow-up Policies for Patients with Malignant Disease. Medical Decision Making, 1991, 11, 131-139.	2.4	19
149	Levels of sex hormones have limited effect on cognition in older men with or without prostate cancer. Critical Reviews in Oncology/Hematology, 2010, 73, 167-175.	4.4	19
150	Surveillance for stage I testicular seminoma. Urologic Oncology: Seminars and Original Investigations, 2001, 6, 139-143.	1.6	18
151	Major 30â€day complications after radical radiotherapy. Cancer, 2009, 115, 293-302.	4.1	18
152	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. Radiotherapy and Oncology, 2017, 123, 459-465.	0.6	18
153	Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Canadian Journal of Urology, 2002, 9, 1479-85.	0.0	18
154	Renal glomerulopathies associated with Hodgkin's disease. Cancer, 1985, 56, 874-875.	4.1	17
155	Recursive Partitioning Analysis of Prognostic Factors for Survival in Patients With Advanced Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1169-1176.	0.8	17
156	Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting. Canadian Urological Association Journal, 2013, 2, 500.	0.6	17
157	Directly Improving the Quality of Radiation Treatment Through Peer Review: AÂCross-sectional Analysis of Cancer Centers Across a Provincial Cancer Program. International Journal of Radiation Oncology Biology Physics, 2017, 98, 521-529.	0.8	17
158	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Canadian Urological Association Journal, 2016, 10, 25.	0.6	17
159	Management of Low-Stage Testicular Seminoma. Urologic Clinics of North America, 2007, 34, 127-136.	1.8	16
160	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgenâ€receptorâ€“targeted therapy for metastatic castrationâ€resistant prostate cancer. Cancer, 2021, 127, 2587-2594.	4.1	16
161	GU radiation oncologists consensus on bone loss from androgen deprivation. Canadian Journal of Urology, 2006, 13, 2962-6.	0.0	16
162	High-intensity focused ultrasound for prostate cancer: a practice guideline. Canadian Urological Association Journal, 2013, 4, 232.	0.6	15

#	Article	IF	Citations
163	RECPAM analysis of prognostic factors in patients with Stage III breast cancer. Breast Cancer Research and Treatment, 1990, 16, 231-242.	2.5	14
164	Evolving concepts in stage I seminoma. BJU International, 2009, 104, 1357-1361.	2.5	14
165	PMH 9907: Longâ€term outcomes of a randomized phase 3 study of shortâ€term bicalutamide hormone therapy and doseâ€escalated externalâ€beam radiation therapy for localized prostate cancer. Cancer, 2016, 122, 2595-2603.	4.1	14
166	Acute Toxicity of Conventional Radiation Therapy for High-Risk Prostate Cancer in EORTC Trial 22863. European Urology, 2002, 42, 125-132.	1.9	13
167	Contemporary Management of Stage I and II Seminoma. Current Urology Reports, 2013, 14, 525-533.	2.2	13
168	Treatment-related toxicity and symptom-related bother followingpostoperative radiotherapy for prostate cancer. Canadian Urological Association Journal, 2013, 4, 105.	0.6	13
169	The experience of patients with early-stage testicular cancer during the transition from active treatment to follow-up surveillance. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 168.e11-168.e20.	1.6	13
170	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. Clinical Genitourinary Cancer, 2018, 16, e193-e199.	1.9	13
171	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. European Urology Oncology, 2021, 4, 289-296.	5.4	13
172	Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer. Canadian Journal of Urology, 2002, 9, 1444-52; discussion 1453.	0.0	13
173	The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy Â± neoadjuvant androgen deprivation. International Journal of Radiation Oncology Biology Physics, 2004, 58, 53-58.	0.8	12
174	The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 60-69.	4.9	12
175	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. Canadian Urological Association Journal, 2017, 12, 59-66.	0.6	12
176	Do radiation oncology outreach clinics affect the use of radiotherapy?. Radiotherapy and Oncology, 2018, 127, 143-149.	0.6	12
177	The impact of irregularly rising prostate-specific antigen and â€œimpending failureâ€•on the apparent outcome of localized prostate cancer following radiotherapy. International Journal of Radiation Oncology Biology Physics, 2001, 49, 957-963.	0.8	11
178	Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial. Cancer, 2018, 124, 1132-1140.	4.1	11
179	Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. European Urology Oncology, 2019, 2, 437-442.	5.4	11
180	Effects of six months of aerobic and resistance training on metabolic markers and bone mineral density in older men on androgen deprivation therapy for prostate cancer. Journal of Geriatric Oncology, 2020, 11, 1074-1077.	1.0	11

#	Article	IF	Citations
181	Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 2021, 4, e2114694.	5.9	11
182	The influence of transurethral resection of prostate on prognosis of patients with adenocarcinoma of the prostate treated by radical radiotherapy. Radiotherapy and Oncology, 1994, 31, 41-50.	0.6	10
183	Inverse Relationship Between Biochemical Outcome and Acute Toxicity After Image-Guided Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 608-616.	0.8	10
184	National survey addressing the information needs of primary care physicians: Side effect management of patients on androgen deprivation therapy. Canadian Urological Association Journal, 2014, 8, 227.	0.6	10
185	The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. Canadian Urological Association Journal, 2016, 10, 204.	0.6	10
186	Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. Radiotherapy and Oncology, 2020, 149, 240-245.	0.6	10
187	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. Current Oncology, 2021, 28, 107-114.	2.2	10
188	Economic Evaluation of a Geriatric Oncology Clinic. Cancers, 2022, 14, 789.	3.7	10
189	Treatment Options, Prognostic Factors and Selection of Treatment in Stage I Seminoma. Oncology Research and Treatment, 2006, 29, 592-598.	1.2	9
190	Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement. Canadian Urological Association Journal, 2013, 2, 95.	0.6	9
191	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. BJU International, 2018, 122, 814-822.	2.5	8
192	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. International Journal of Radiation Oncology Biology Physics, 2019, 104, 61-66.	0.8	8
193	[¹⁸F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	1.9	8
194	Controversies in the management of testicular seminoma. Urologic Oncology, 2002, 20, 227-233.	1.5	8
195	The costs of cancer therapy. European Journal of Cancer & Clinical Oncology, 1990, 26, 223-225.	0.7	7
196	Management of Stage I Testicular Seminoma. Hematology/Oncology Clinics of North America, 2011, 25, 503-516.	2.2	7
197	The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiation Oncology, 2017, 12, 50.	2.7	7
198	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castrationâ€resistant prostate cancer treated with Radiumâ€223. Cancer Medicine, 2021, 10, 5775-5782.	2.8	7

#	Article	IF	Citations
199	Testicular radiation for primary seminoma in a solitary testis. Canadian Journal of Urology, 2006, 13, 2975-7.	0.0	7
200	A Dose-Volume Histogram Analysis of the Seminal Vesicles in Men Treated with Conformal Radiotherapy to â€˜Prostate Aloneâ€™. Clinical Oncology, 2002, 14, 298-302.	1.4	6
201	Bisphosphonate Prescriptions in Men With Androgen Deprivation Therapy Use. JAMA - Journal of the American Medical Association, 2014, 312, 2285.	7.4	6
202	In Regard to Yerramilli etÂalâ€™s â€œPalliative Radiotherapy for Oncologic Emergencies in the Setting of COVID-19: Approaches to Balancing Risks and Benefitsâ€• Advances in Radiation Oncology, 2020, 5, 595-596.	1.2	6
203	Discrepancy in pathology reports upon second review of radical orchiectomy specimens for testicular germ cell tumors. Canadian Urological Association Journal, 2020, 14, 411-415.	0.6	6
204	Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors. European Urology Open Science, 2022, 40, 46-53.	0.4	6
205	Stage I seminoma: What should a practicing uroâ€oncologist do in 2009?. International Journal of Urology, 2009, 16, 544-551.	1.0	5
206	â€œI sleep better at night:â€•How peer review of radiation treatment plans indirectly improves quality of care across radiation treatment programs. Practical Radiation Oncology, 2017, 7, 281-288.	2.1	5
207	The Capital Investment Strategy for Radiation therapy in Ontario: A Framework to Ensure Access to Radiation Therapy. Advances in Radiation Oncology, 2020, 5, 318-324.	1.2	5
208	Electronic Surveillance of Testicular Cancer: Understanding Patient Perspectives on Access to Electronic Medical Records. Journal of Oncology Practice, 2009, 5, 177-181.	2.5	4
209			

#	Article	IF	Citations
217	Testicular seminoma: Scattered radiation dose to the contralateral testis in the modern era. Practical Radiation Oncology, 2018, 8, e57-e62.	2.1	3
218	Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT. BMC Cancer, 2018, 18, 1031.	2.6	3
219	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. Urology, 2020, 138, 69-76.	1.0	3
220	Hospital-level Effects Contribute to Variations in Prostate Cancer Quality of Care. European Urology Oncology, 2021, 4, 494-497.	5.4	3
221	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. Canadian Urological Association Journal, 2021, 16, .	0.6	3
222	Alleviation of chemotherapy induced emesis by oral lorazepam and domperidone. Irish Journal of Medical Science, 1983, 152, 336-338.	1.5	2
223	Is Steroid Receptor Data Useful in Patients with Metastatic Breast Cancer?. American Journal of the Medical Sciences, 1992, 304, 9-13.	1.1	2
224	Regarding Chao et al IJROBP 33(4):831â€“835; 1995. International Journal of Radiation Oncology Biology Physics, 1997, 38, 673-674.	0.8	2
225	A Randomized Phase III Study of Neoadjuvant Hormonal Therapy in Patients with Localized Prostate Cancer. Clinical Genitourinary Cancer, 2006, 5, 235-237.	1.9	2
226	Practical and clinical applications of radiation therapy. Medicine, 2016, 44, 15-19.	0.4	2
227	Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer. European Urology Focus, 2016, 2, 276-283.	3.1	2
228	The management of high-risk, locally advanced, prostate cancer radiation therapy. Canadian Urological Association Journal, 2012, 6, 393-395.	0.6	2
229	Chemotherapy treated hodgkins disease â€" A fifteen year review. Irish Journal of Medical Science, 1986, 155, 300-307.	1.5	1
230	2108 Urethral carcinoma in women: Results of treatment with primary radiotherapy. International Journal of Radiation Oncology Biology Physics, 1997, 39, 294.	0.8	1
231	Re: Vikram, B., The PSA conundrum. Radiother Oncol, 2004. 71(1): p. 1â€“2. Radiotherapy and Oncology, 2004, 73, 252-254.	0.6	1
232	A reliable coding system to define screening prostate-specific antigen tests was developed in a caseâ€“control study. Journal of Clinical Epidemiology, 2005, 58, 639-644.	5.0	1
233	Are carboplatin and radiotherapy equally effective for the adjuvant treatment of stage I seminoma?. Nature Clinical Practice Oncology, 2006, 3, 18-19.	4.3	1
234	Response to â€œIntraoperative Radiotherapy During Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical and Dosimetric Aspectsâ€•(Int J Radiat Oncol Biol PhysÂ2009; in press). International Journal of Radiation Oncology Biology Physics, 2010, 76, 1277.	0.8	1

#	Article	IF	Citations
235	Optimizing computed tomography simulation wait times in a busy radiation medicine program. Practical Radiation Oncology, 2017, 7, e77-e83.	2.1	1
236	Clinical dilemmas in local and regional testis cancer. Canadian Urological Association Journal, 2020, 15, E58-E64.	0.6	1
237	Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. Clinical and Translational Radiation Oncology, 2020, 21, 69-76.	1.7	1
238	Prostate or bone? Comparing the efficacy of image guidance surrogates for pelvis and prostate radiotherapy using accumulated delivered dose. Journal of Medical Imaging and Radiation Sciences, 2021, 52, 14-21.	0.3	1
239	Daily symptom monitoring commonly leads to treatment modification in older adults receiving treatment for metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2022, 40, 82-82.	1.6	1
240	Errors from field placement and organ motion during conformal radiotherapy for prostate cancer. Journal of Radiotherapy in Practice, 2000, 2, 65-73.	0.5	0
241	RESPONSE TO WIECEL AND HINKELBEIN. Radiotherapy and Oncology, 2002, 62, 115-116.	0.6	0
242	Radiotherapy: practical applications and clinical aspects. Medicine, 2004, 32, 17-20.	0.4	0
243	Radiotherapy: practical applications and clinical aspects. Medicine, 2011, 39, 705-710.	0.4	0
244	The management of high-risk, locally advanced, prostate cancer radiation therapy. Canadian Urological Association Journal, 2012, 6, .	0.6	0
245	Reply to monitoring of seminoma patients with serum markers. Cancer, 2013, 119, 2511-2512.	4.1	0
246	IMRT utilization in Ontario: qualitative deployment evaluation. International Journal of Health Care Quality Assurance, 2014, 27, 742-759.	0.9	0
247	Regional Therapy Might Have a Role. International Journal of Radiation Oncology Biology Physics, 2017, 99, 511.	0.8	0
248	MRI-Guided Focal HDR Brachytherapy as Monotherapy for Prostate Cancer: Early Feasibility and Quality of Life Study. Brachytherapy, 2019, 18, S67.	0.5	0
249	211 Developing a Strategic Plan for a Provincial Radiation Treatment Program to Advance the Quality of Care for Patients. Radiotherapy and Oncology, 2019, 139, S88-S89.	0.6	0
250	Local Failure in High-grade Prostate Cancer: An Elusive but Important Outcome and Target for Clinical Trials. European Urology, 2020, 77, 209-210.	1.9	0
251	191: Advancing A Provincial Strategic Plan: Translating Theory Into Action to Improve The Quality of Care for Patients. Radiotherapy and Oncology, 2020, 150, S81-S82.	0.6	0
252	A Canadian approach to the regionalization of testis cancer: A review. Canadian Urological Association Journal, 2020, 14, 346-351.	0.6	0

#	Article	IF	Citations
253	Variability in Steroid Prophylaxis for Radiation-Induced Pain Flare: Practice of Canadian Radiation Oncologists. Journal of Palliative Medicine, 2021, 24, 965-966.	1.1	0
254	Stage II Seminoma and Advanced Disease. , 2011, , 197-205.		0
255	Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy. Technical Innovations and Patient Support in Radiation Oncology, 2022, 21, 64-70.	1.9	0
256	Remote symptom monitoring (RSM) during treatment for metastatic prostate cancer (mPC) in older men: Feasibility and efficacy.. Journal of Clinical Oncology, 2022, 40, 12056-12056.	1.6	0